COVAXIN gets a nod for human trials


Post 6 months and millions of infections, COVID-19 is showing no signs of stopping, even as experts worry about the emergence of the second wave of infections. Researchers are fighting a race against time to develop the world’s first vaccine and prevent further spread of the deadly infection.

Leading vaccine maker from the country, Hyderabad based Bharat Biotech won the approvals from Drug Controller General of India (DGCI) to start phase I and II clinical trials of its vaccine prototype, named ‘COVAXIN’ in the country. This is the first such company which has received a go-ahead to start the clinical trials.

The vaccine has been produced by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and National Institue of Virology (NIV) by using an inactive version of the vaccine. Pre-clinical trials for the same have shown good immune response in the body and have been termed “safe” for use.

India, which is one of the biggest vaccine production hubs worldwide is seeing as many as 30 vaccine candidates being developed in the country. Pune-based Serum Institue of India (SII) is working with many global vaccine firms, including the University of Oxford to ramp up production of their vaccine if it is approved for use post the end of clinical trials.

Source: Drug Controller General of India